Equities analysts predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will report sales of $4.53 billion for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.41 billion and the highest is $4.76 billion. Teva Pharmaceutical Industries reported sales of $5.46 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 17%. The company is scheduled to report its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $18.85 billion for the current fiscal year, with estimates ranging from $18.71 billion to $19.05 billion. For the next fiscal year, analysts forecast that the company will report sales of $17.89 billion, with estimates ranging from $17.22 billion to $18.15 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.53 by $0.11. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.54 billion. During the same period last year, the firm posted $1.00 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was down 19.4% compared to the same quarter last year.
In related news, insider Deborah A. Griffin sold 2,376 shares of the business’s stock in a transaction on Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total value of $56,334.96. Following the completion of the sale, the insider now owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Richard Daniell sold 2,488 shares of the business’s stock in a transaction on Tuesday, September 18th. The stock was sold at an average price of $23.69, for a total transaction of $58,940.72. Following the completion of the sale, the vice president now directly owns 2,488 shares of the company’s stock, valued at approximately $58,940.72. The disclosure for this sale can be found here. In the last three months, insiders sold 6,531 shares of company stock valued at $152,749. 0.43% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. PointState Capital LP acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $161,826,000. FMR LLC boosted its stake in Teva Pharmaceutical Industries by 19.1% during the 3rd quarter. FMR LLC now owns 24,481,936 shares of the company’s stock worth $527,341,000 after purchasing an additional 3,921,785 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth $90,746,000. Renaissance Technologies LLC boosted its stake in Teva Pharmaceutical Industries by 348.1% during the 2nd quarter. Renaissance Technologies LLC now owns 4,036,863 shares of the company’s stock worth $98,177,000 after purchasing an additional 3,135,900 shares during the last quarter. Finally, Beck Mack & Oliver LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth $64,484,000. 65.10% of the stock is owned by institutional investors.
TEVA traded down $0.39 during trading on Monday, reaching $23.45. 6,637,061 shares of the company’s stock were exchanged, compared to its average volume of 10,918,274. Teva Pharmaceutical Industries has a 1 year low of $11.44 and a 1 year high of $25.96. The company has a current ratio of 0.94, a quick ratio of 0.61 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $24.13 billion, a PE ratio of 7.39, a P/E/G ratio of 7.28 and a beta of 0.77.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: What is dollar cost averaging (DCA)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.